CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Astrazeneca PLC (AZN) / laroprovstat
Forward catalyst · AZN

laroprovstat

Sponsor Astrazeneca PLC · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

laroprovstat is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Jan 4, 2027 (day precision, medium confidence), tied to trial NCT07000136. The asset is in Phase 3 and currently active not recruiting, studied in Heterozygous Familial Hypercholesterolaemia. It appears across 5 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-01-04
As disclosedJan 4, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT07000136
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAstraZeneca
Listed asAZN
Condition(s)Heterozygous Familial Hypercholesterolaemia

All tracked catalysts for laroprovstat

DateEventConfidenceTrial
2027-01-04READOUTmediumNCT07000136
2027-01-11READOUTmediumNCT07000123
2027-02-22READOUTmediumNCT06834932
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More AZN catalysts